Urovant Sciences is a biopharmaceutical company advancing urologic patient care through development of innovative therapies and exceptional licensing opportunities.

Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology and their well-being. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated. 

More than 30 million people in the U.S. live with the bothersome symptoms of overactive bladder (OAB). The FDA has approved Gemtesa® (vibegron) for the treatment of overactive bladder in adult patients.

Click here for more information.

Urovant Sciences is investigating vibegron, a ß3 adrenergic agonist, for the treatment of OAB in men with benign prostatic hyperplasia, and URO-902, a novel gene therapy, for the treatment of OAB.